Spiriva

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Obstructive Pulmonary DiseaseBronchiectasis

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

Spiriva

Boehringer Ingelheim

Approved

32

Veramyst

GSK

Preclinical

463

Xolair

Roche

Preclinical

254

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

355

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

306

Celexa

AbbVie

Preclinical

17

Spiriva

Boehringer Ingelheim

Preclinical

88

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

89

Aciphex

Akero Therapeutics

Preclinical

210

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1Show 13 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease3 trials

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Completed·Boehringer Ingelheim··NCT02172547·10,821 enrolled

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

Completed·Boehringer Ingelheim··NCT02177318·3,588 enrolled

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed·Boehringer Ingelheim·Phase 2·NCT02242266·121 enrolled

Asthma3 trials

Specific Use-Result of Spiriva Respimat® in Asthmatics

Completed·Boehringer Ingelheim··NCT03188120·193 enrolled

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Completed·PPearl Therapeutics, Inc.·Phase 2/3·NCT03358147·1,077 enrolled

Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

Completed·Boehringer Ingelheim··NCT02489981·359 enrolled

Bronchiectasis1 trial

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT02546297·90 enrolled

Salmeterol1 trial

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Completed·Boehringer Ingelheim·Phase 1·NCT02254174·36 enrolled

Tics1 trial

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Completed·Boehringer Ingelheim·Phase 1·NCT02263976·101 enrolled

8 more indications

Clinical Trial1 trial

ANTES B+ Clinical Trial

Terminated·FFundacio Privada Mon Clinic Barcelona·Phase 4·NCT06282861·48 enrolled

Efficacy and Safety1 trial

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Completed·AstraZeneca·Phase 4·NCT00496470·660 enrolled

Function1 trial

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Completed·Boehringer Ingelheim··NCT02173769·1,845 enrolled

Treatment1 trial

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

Completed·PPearl Therapeutics, Inc.·Phase 3·NCT02347072·80 enrolled

COPD1 trial

Description of the Ability to Learn How to Handle Inhaler Devices in COPD

Completed·UUniversity Hospital, Bordeaux·Phase 4·NCT02813200·24 enrolled

Dyspnea1 trial

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

Completed·LLaval University·Phase 4·NCT02567214·50 enrolled

CAR1 trial

SPIRIVA in Ususal Care

Completed·Boehringer Ingelheim·Phase 4·NCT00274079·395 enrolled

Scar1 trial

PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium

Completed·AstraZeneca·Phase 1·NCT03097380·19 enrolled

Details

Drug Info

Related News